Skip to main content
Profound Medical Corp. logo

Profound Medical Corp. — Investor Relations & Filings

Ticker · PROF TSX Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2020-01-22 Regulatory Filings
Country CA Canada
Listing TSX PROF

About Profound Medical Corp.

https://profoundmedical.com/

Profound Medical Corp. is a commercial-stage medical technology company specializing in incision-free ablative therapies. Its core product is TULSA-PRO®, a therapeutic platform designed for the treatment of localized prostate cancer, radiorecurrent prostate cancer, and benign prostatic hyperplasia (BPH). TULSA-PRO utilizes a robotically controlled, transurethral ultrasound ablation procedure guided by real-time Magnetic Resonance (MR) imaging. This system employs closed-loop temperature feedback to ensure precise and customizable tissue ablation, prioritizing patient safety and minimizing complications. The technology merges MR imaging, thermal ultrasound, and robotics to offer a durable and accurate treatment delivery method.

Recent filings

Filing Released Lang Actions
Prospectus (non pricing) supplement - English.pdf
Regulatory Filings
2020-01-22 English
News release - English.pdf
Regulatory Filings
2020-01-22 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a proposed public offering of common shares by Profound Medical Corp. It discusses the intention to file a preliminary prospectus supplement and provides details about the offering, underwriters, use of proceeds, and regulatory filings related to the offering. There are no financial statements, detailed financial performance data, or management discussion of results. The document is an announcement of a capital raising event and related filings, not the filings themselves or detailed financial reports. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (7749 characters) supports it being a full announcement rather than a brief notice or a report publication announcement.
2020-01-21 English
Draft shelf prospectus supplement – English.pdf
Regulatory Filings
2020-01-21 English
News release - English.pdf
Capital/Financing Update Classification · 90% confidence The document is a press release announcing preliminary unaudited revenues for the fourth quarter and full year 2019, along with a commercialization update for a medical device. It provides revenue figures but explicitly states they are preliminary and unaudited, and it does not contain comprehensive financial statements or detailed financial analysis. The document also includes forward-looking statements and business updates rather than a full financial report. It is not an earnings release since it provides preliminary and unaudited revenue data rather than finalized quarterly results. It is not an annual report or interim report because it lacks detailed financial statements and analysis. The document is best classified as a Capital/Financing Update (CAP) because it discusses revenue updates and commercialization progress, which relate to the company's financial and capital status. The document length (8728 characters) is sufficient to be more than a simple announcement, but it does not meet the criteria for a full financial report. Therefore, the most appropriate classification is CAP with high confidence.
2020-01-10 English
News release - English.pdf
Regulatory Filings
2020-01-10 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.